Blood antioxidant capacity change in patients with the «dry» form of age-related macular degeneration treated with polarized polychromatic non-coherent light and dynamic electromyostimulation
- Authors: Saifullina FR1, Sharafieva RZ1,2, Pogorel’tsev VI3, Fayzrahmanova FM2, Abdulaeva EA1
-
Affiliations:
- Kazan State Medical Academy, Kazan, Russia
- Out-Patient’s Clinic of Kazan Scientific Centre of Russian Academy of Science, Kazan, Russia
- Kazan State Medical University, Kazan, Russia
- Issue: Vol 93, No 6 (2012)
- Pages: 994-996
- Section: Actual problems of ophthalmology
- URL: https://journals.rcsi.science/kazanmedj/article/view/2129
- DOI: https://doi.org/10.17816/KMJ2129
- ID: 2129
Cite item
Full Text
Abstract
Aim. To assess the antioxidant capacity in patients with the «dry» form of age-related macular degeneration before and after combined treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation. Methods. Two groups of patients with the «dry» form of age-related macular degeneration were examined. 40 patients (80 eyes) from the main group were treated using combined treatment and 39 patients (78 eyes) in the group of control who were treated conventionally. The integral blood antioxidant capacity was measured by galvanometry. Results. Blood antioxidant capacity in healthy subjects is 26.0 kC/l. In patients of the main group blood antioxidant capacity before the treatment was equal to 22.81±0.27 kC/l, compared to 22.17±0.20 kC/l in control group (total mean value 22.49±0.27 kC/l). There was a relevant elevation of the blood antioxidant capacity at the late stages after the treatment - up to 12 months, compared to only 2 months in the control group. Visual acuity in patients of the main group before the treatment was 0.87±0.02, after the treatment was finished - 0.96±0,01 (p <0.001), 2 months after the treatment - 0.95±0.01 (p <0.001), 6 months after the treatment - 0.96±0.01 (p <0.001), 12 months after the treatment - 0.95±0.01 (p <0.001). Visual acuity in patients of the control group before the treatment was 0.91±0.02, after the treatment was finished - 0.95±0.02 (p <0.05), 2 months after the treatment - 0.94±0.02 (p <0.05), 6 months after the treatment - 0.92±0.02 (p >0.05). 12 months after the treatment the visual acuity deteriorated compared to the treatment start and was measured as 0.89±0.02. Conclusion. There is a decrease of blood antioxidant capacity (22.49±0.27 kC/l) in patients with the «dry» form of age-related macular degeneration; a relevant increase of blood antioxidant capacity and visual acuity can be observed up to 12 months after the treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation.
Full Text
##article.viewOnOriginalSite##About the authors
F R Saifullina
Kazan State Medical Academy, Kazan, Russia
R Z Sharafieva
Kazan State Medical Academy, Kazan, Russia; Out-Patient’s Clinic of Kazan Scientific Centre of Russian Academy of Science, Kazan, Russia
Email: rezinshar@rambler.ru
V I Pogorel’tsev
Kazan State Medical University, Kazan, Russia
F M Fayzrahmanova
Out-Patient’s Clinic of Kazan Scientific Centre of Russian Academy of Science, Kazan, Russia
E A Abdulaeva
Kazan State Medical Academy, Kazan, Russia
References
- Аветисов С.Э., Кисёлева Т.Н., Лагутина Ю.М., Кравчук Е.А. Влияние вазоактивных препаратов на зрительные функции и глазной кровоток у больных с ранними проявлениями возрастной макулярной дегенерации // Вестн. офтальм. - 2007. - Т. 123, №3. - С. 1-4.
- Астахов Ю.С., Лисочкина А.Б., Щадричев Ф.Е. Возрастная макулярная дегенерация. Клинические рекомендации. Офтальмология / Под ред. Л.К. Мошетовой, А.П. Нестерова, Е.А. Егорова. - М.: ГЭОТАР-Медиа, 2006. - С. 164-188.
- Журавлёва Л.В. Ретилаламин в комплексном лечении возрастной макулярной дегенерации // Вестн. Рос. военно-мед. акад. - 2005. - №1. - С. 3-6.
- Егоров Е.А., Кац Д.В., Елисеева Т.О., Ермакова М.В. Современные направления в лечении инволюционной центральной хориоретинальной дистрофии // Актуал. вопр. терап. - 2006. - №5. - С. 2-6.
- Морозов В.И., Яковлев А.А. Фармакотерапия глазных болезней. Справочник. - М.: Медицина, 2001. - С. 239-241.
- Налобнова Ю.В., Егоров Е.А., Ставицкая Т.В., Асророва Г.К. Применение цитомединов в офтальмологии // Клин. офтальм. - 2003. - №2. - С. 176-178.
- Нащенкова О.В. Применение биологически активных веществ в лечении возрастной макулодистрофии // Клин. офтальм. - 2004. - Т. 5, №2. - С. 82.
- Погорельцев В.И., Зиятдинова Г.К., Будников Г.К. Применение метода кулонометрии в диагностике антиоксидантного статуса организма человека. - Казань: КГМУ, 2004. - 53 с.
- Chong E.W., Wong T.Y., Кreis A.J. et al. Dietari antioxidants and primary prevention of age-related macular degeneration: systematic review and meta-analysis // BMJ. - 2007. - Vol. 335. - P. 755.
- San Giovanni J.P., Chew E.Y., Clemons T.E. et al. The relationship of dietary carotenoids and vitamin A, E and C intake with age-related makular degeneration in a case-control study AREDS report number 22 // Arch. Ophthalmol. - 2007. - Vol. 125. - P. 1225-1232.
- Van Leeuwen R., Boekhoorn S., Vingerling J.R. et al. Dietary intake of antiozidants and risk age-related makular degeneration // JAMA. - 2005. - Vol. 294. - P. 3101-3107.
- Williams R.A., Brady B.L., Thomas R.J. Risk factors for age-related macular degeneration // Arch. Ophthalmol. - 1998. - Vol. 116. - P. 514-520.
